Prevalence of BRCA1 c.5161C>T mutation in cancer patients from Bashkortostan

Introduction. Despite the significant progress in investigation of genetic susceptibility to cancers, there are still unclear questions in the field of molecular epidemiology. Numerous new data obtained using modern sequencing technologies require large case/control studies in different populations.

The study objective – to investigate the prevalence of BRCA1*c.5161C>T mutation in unselected breast, ovarian and prostate cancer patients from Bashkortostan.

Materials and methods. In the presented study, the prevalence of the BRCA1*c.5161C>T mutation was assessed in breast cancer, ovarian cancer and prostate cancer patients (n = 696). The study cohorts includes individuals of Tatar and Bashkir ethnic origin living in Bashkortostan Republic.

Results. The BRCA1 mutation c.5161C>T was detected in patients with breast cancer, ovarian cancer and prostate cancer in individuals of Tatar ethnic origin with a frequency of ~1,3 % (6/449), but not in Bashkirs. This mutation was also detected in two individuals of control group (2/700). We conclude that the contribution of the BRCA1 mutation c.5161C>T to hereditary breast, ovarian and prostate cancers, is likely to be small in Bashkortostan Republic.

Conclusion. Further research will be required to investigate whether this mutation also plays a role in other populations of Turkic origin.

1. Ferlay J., Colombet M., Soerjomataram I. et al. Cancer statistics for the year 2020: an overview. Int J Cancer 2021. DOI: 10.1002/ijc.33588.

2. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660.

3. Moscow: P.A. Herzen Moscow State Medical Research Institute – a branch of the Federal State Budgetary Institution «NMIC of Radiology» of the Ministry of Health of Russia, 2020. 252 с. [Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinskij, A.O. Shakhzadova. Moscow: 2020. 252 p. (In Russ.).

4. Cancer fact sheets. Cancer today. Avaliable at: https://gco.iarc.fr/today/fact-sheetscancers.

5. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.

6. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol 2012;30(2):143–8. DOI: 10.1007/s00345-011-0801-1.

7. Kuchenbaecker K.B., Hopper J.L., Barnes D.R. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317(23):2402–16. DOI: 10.1001/jama.2017.7112.

8. Nyberg T., Frost D., Barrowdale D. et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. EurUrol 2020;77(1):24–35. DOI: 10.1016/j.eururo.2019.08.025.

9. Bermisheva M.A., Bogdanova N.V., Gilyazova I.R. et al. Ethnic features of genetic susceptibility to breast cancer. Genetika = Genetics 2018;54(2):226–34. (In Russ.).

10. Nikitin A.G., Brovkina O.I., Khodyrev D.S. et al. Creating a public mutation database oncoBRCA: bioinformatic problems and solutions. Klinicheskaya praktika = Clinical Practice 2020;11(1):21–9. (In Russ.). DOI: 10.17816/clinpract25860.

11. Ethnogenomics of the peoples of Central Eurasia: the structure of the gene pool and the genetics of hereditary pathology. Ufa: Gilem, 2014. 488 p. (In Russ.).

12. Hu C., Hart S.N., Gnanaolivu R. et al. A Population-based study of genes previously implicated in breast cancer. N Engl J Med 2021;384(5):440–51. DOI: 10.1056/NEJMoa2005936.

13. Levy-Lahad E., Catane R., Eisenberg S. et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60(5):1059–67.

14. Cybulski C., Kluźniak W., Huzarski T. et al. The spectrum of mutations predisposing to familial breast cancer in Poland. Int J Cancer 2019;145(12):3311–20. DOI:10.1002/ijc.32492.

15. Savanevich A., Ashuryk O., Cybulski C. et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. Hereditary Cancer in Clinical Practice 2021;19:13. DOI: 10.1186/s13053-021-00169-y.

16. Yoshida R., Watanabe C., Yokoyama S. et al. Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X. Oncotarget 2019;10(35):3276–84. DOI: 10.18632/oncotarget.26852.

17. Alvarez C., Tapia T., Perez-Moreno E. et al. BRCA1 and BRCA2 founder mutations account for 78 % of germline carriers among hereditary breast cancer families in Chile. Oncotarget 2017;8(43):74233–43. DOI: 10.18632/oncotarget.18815.

18. Yusupov Y.M., Skhalyakho R., Agdzhoyan A.T. et al. Analysis of the gene pool of the south eastern bashkirs in the context of their clan structure (according to the ʏ chromosome polymorphism). Moscow University Anthropology Bulletin. Anthropology 2019;4:54–66. (In Russ.). DOI: 10.32521/2074-8132.2019.4.054-066.

19. Laitman Y., Borsthein R.T., StoppaLyonnet D. et al. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel Breast Cancer Res Treat 2011;127(2):489–95. DOI: 10.1007/s10549-010-1217-0.

20. Cao W., Wang X., Gao Y. et al. BRCA1 Germ-line mutations and tumor characteristics in eastern chinese women with familial breast cancer. Anat Rec (Hoboken) 2013;296(2):273–8. DOI: 10.1002/ar.22628.

21. Muendlein A., Rohde B.H., Gasser K. et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol 2015;141(11):2005–12. DOI: 10.1007/s00432-015-1986-2.

22. Abdel-Razeq H., Abujamous L., Abunasser M. et al. Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan. Sci Rep 2021;11:14906. DOI: 10.1038/s41598-021-94403-1.

23. Abu-Helalah M., Azab B., Mubaidi R. et al. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. Sci Rep 2020;10:17573. DOI: 10.1038/s41598-020-74250-2.

24. Novikova E.I., Kudinova E.A., Bozhenko V.K., Solodkiy V.A. Characteristics of BRCA-associated breast cancer in the population of the Russian Federation. Vestnik RGMU 2021;1:26–32. (In Russ.). DOI: 10.24075/vrgmu.2021.006.

25. Sokolenko A.P., Sokolova T.N., Ni V.I. et al. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Breast Cancer Res Treat 2020;184(1):229–35. DOI: 10.1007/s10549-020-05827-8.

26. Brovkina O.I., Gordiev M.G., Enikeev R.F. et al. Reparation system genes: population differences in hereditary ovarian and breast cancer determined by next-generation sequencing. Tumors of female reproductive system 2017;2(13):61–7. (In Russ.). DOI: 10.17650/1994-4098-2017-13-2-61-67.

27. Snigireva G.P., Rumyantseva V.A., Novikova E.I. et al. Algorithm of molecular genetic investigation to identify hereditary BRCA-associated breast cancer. Al’manah klinicheskoj mediciny = Almanac of Clinical Medicine 2019;47(1):54–65. (In Russ.). DOI:10.18786/2072-0505-2019-47-002.

28. Kadouria L., Rottenberga Y., Zicka A. et al. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization. Lung Cancer 2019;137:48–51. DOI: 10.1016/j.lungcan.2019.09.008.

29. Tutt A.N.J., Garber J.E., Kaufman B. et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2394–405. DOI: 10.1056/NEJMoa2105215.